Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $111.6 million.

  • 4D Molecular Therapeutics' Non-Current Assets rose 1965.67% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $590.6 million, marking a year-over-year increase of 9794.34%. This contributed to the annual value of $125.5 million for FY2024, which is 18970.74% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Non-Current Assets stood at $111.6 million for Q3 2025, which was up 1965.67% from $170.4 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Non-Current Assets peaked at $183.2 million during Q1 2025, and registered a low of $5.6 million during Q1 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Non-Current Assets averaged around $74.0 million, with its median value being $67.5 million (2024).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Non-Current Assets soared by 161289.87% in 2021 and then tumbled by 5747.73% in 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' Non-Current Assets (Quarter) stood at $97.2 million in 2021, then tumbled by 57.48% to $41.3 million in 2022, then grew by 4.76% to $43.3 million in 2023, then surged by 189.71% to $125.5 million in 2024, then decreased by 11.04% to $111.6 million in 2025.
  • Its Non-Current Assets stands at $111.6 million for Q3 2025, versus $170.4 million for Q2 2025 and $183.2 million for Q1 2025.